Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
ANZ J Surg ; 83(12): 968-72, 2013 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-23802729

RESUMO

BACKGROUND: Colorectal cancer surgery carries a high risk of venous thromboembolism (VTE) but the optimal duration of thromboprophylaxis is unknown. The cost-effectiveness of extended prophylaxis is not known in Australasia. The aims of this study were to determine the 30-day incidence of VTE in patients undergoing colorectal cancer surgery, to audit compliance with thromboprophylaxis protocols and to estimate the cost of treating all patients for 28 days with enoxaparin. METHODS: Patients undergoing elective colorectal cancer surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database. Case note review was conducted for patient demographics, VTE risk factors, types of thromboprophylaxis used, complications, readmission rate and VTE rate. Documented compliance with unit VTE protocols was calculated. The cost of treating all patients with enoxaparin as prophylaxis for 28 days was then estimated. RESULTS: A total of 254 patients were identified. The in-hospital VTE rate was 0.79% (2 out of 254). The post-discharge VTE rate was 0.39% (1 out of 254). Compliance with thromboprophylaxis protocols was excellent. Pharmacological thromboprophylaxis was used in 97% of patients, graduated compression stockings in 84% and pneumatic compression devices in 53%. The estimated cost of extended prophylaxis for all 254 patients was $32,308.80. CONCLUSIONS: We have demonstrated excellent compliance with in-hospital thromboprophylaxis. Hence, we have low VTE rates in-particular, post-discharge VTE. The infrequency of post-discharge VTE means that the cost-effectiveness of extended prophylaxis might be questioned.


Assuntos
Anticoagulantes/administração & dosagem , Neoplasias Colorretais/cirurgia , Enoxaparina/administração & dosagem , Complicações Pós-Operatórias/prevenção & controle , Tromboembolia Venosa/prevenção & controle , Idoso , Anticoagulantes/economia , Austrália/epidemiologia , Protocolos Clínicos , Análise Custo-Benefício , Procedimentos Cirúrgicos Eletivos , Enoxaparina/economia , Feminino , Humanos , Dispositivos de Compressão Pneumática Intermitente/estatística & dados numéricos , Masculino , Cooperação do Paciente , Complicações Pós-Operatórias/epidemiologia , Embolia Pulmonar/economia , Embolia Pulmonar/epidemiologia , Embolia Pulmonar/prevenção & controle , Fatores de Risco , Tromboembolia Venosa/economia , Tromboembolia Venosa/epidemiologia , Trombose Venosa/economia , Trombose Venosa/epidemiologia , Trombose Venosa/prevenção & controle
2.
Dalton Trans ; (10): 1601-9, 2004 May 21.
Artigo em Inglês | MEDLINE | ID: mdl-15252610

RESUMO

Reactions between HC triple bond CC triple bond CSiMe3 and several ruthenium halide precursors have given the complexes Ru(C triple bond CC triple bond CSiMe3)(L2)Cp'[Cp'= Cp, L = CO (1), PPh3 (2); Cp' = Cp*, L2= dppe (3)]. Proto-desilylation of 2 and 3 have given unsubstituted buta-1,3-diyn-1-yl complexes Ru(C triple bond CC triple bond CH)(L2)Cp'[Cp'= Cp, L = PPh3 (5); Cp'= Cp*, L2 = dppe (6)]. Replacement of H in 5 or 6 with Au(PR3) groups was achieved in reactions with AuCl(PR3) in the presence of KN(SiMe3)2 to give Ru(C triple bond CC triple bond CAu(PR3)](L2)Cp'[Cp' = Cp, L = PPh3, R = Ph (7); Cp' = Cp*, L2= dppe, R = Ph (8), tol (9)]. The asymmetrically end-capped [Cp(Ph3P)2Ru]C triple bond CC triple bond C[Ru(dppe)Cp*] (10) was obtained from Ru(C triple bond CC triple bond CH)(dppe)Cp* and RuCl(PPh3)2Cp. Single-crystal X-ray structural determinations of and are reported, with a comparative determination of the structure of Fe(C triple bond CC triple bond CSiMe3)(dppe)Cp* (4), and those of a fifth polymorph of [Ru(PPh3)2Cp]2(mu-C triple bond CC triple bond C) (12), and [Ru(dppe)Cp]2(mu-C triple bond CC triple bond C) (13).

3.
Chem Commun (Camb) ; (8): 960-1, 2004 Apr 21.
Artigo em Inglês | MEDLINE | ID: mdl-15069494

RESUMO

Elimination of AuX(PR3)(X = halogen, R = Ph, tol) occurs readily in reactions between compounds containing C(sp)- or C(sp2)-X bonds and alkynyl or polyynyl gold(I) complexes; this reaction has been applied to the syntheses of complexes containing a variety of metal centres linked by C(n) chains (n up to 16).

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...